Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. - Wikidata - wikimedia - TriplyDB

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

http://www.wikidata.org/entity/Q34574834

about

Advances in recombinant antibody manufacturing Glycotherapy: new advances inspire a reemergence of glycans in medicine Selective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor Interactions Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies Fc gamma receptors: glycobiology and therapeutic prospects Post-translational modifications differentially affect IgG1 conformation and receptor binding.Modern Technologies for Creating Synthetic Antibodies for Clinical application.Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.Engineering host cell lines to reduce terminal sialylation of secreted antibodies.Fab fragment glycosylated IgG may play a central role in placental immune evasion.Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding Antibody therapeutics: isotype and glycoform selection.Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.Monoclonal antibodies for prophylaxis and therapy of infectious diseases.The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation Novel human antibody therapeutics: the age of the Umabs.How can we improve antibody-based cancer therapy?Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cells Production of therapeutic antibodies with controlled fucosylation.Pharmacological modulation of chemokine receptor function.GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease.Glycosylation: impact, control and improvement during therapeutic protein production.Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies.Tailoring recombinant protein quality by rational media design.Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies.Minimizing fucosylation in insect cell-derived glycoproteins reduces binding to IgE antibodies from the sera of patients with allergy Controllability analysis of protein glycosylation in CHO cells.Tissue-specific expression of fucosylated glycosphingolipid species in rat prostate.A framework for real-time glycosylation monitoring (RT-GM) in mammalian cell culture.

P2860

Q26764949-B2E48696-8D86-4152-B2F7-C287AA395312 Q27027997-2E52F33A-EC01-42BB-928A-61A87B69EF16 Q27678384-511E93D2-5958-429C-935C-1E871144F782 Q28069362-1A898441-8893-4047-95CB-EE5C028CD3DD Q28076303-C1776684-3210-4ABB-AFB2-3DAB11596F12 Q30384877-1524B57D-5C14-4618-BFE0-CD8C0066D7DB Q30467308-95C6E436-C0B9-441F-B0CE-86EC0EC35923 Q33307815-12FA54B7-9DD3-40E6-A2A7-ED92080B7524 Q33410392-9C851005-CA41-4891-BAB9-AA7D3AFDDFDB Q33661333-F0154828-6C07-4132-BBFC-13CFCE9499CA Q35003386-B036D28A-9508-4BC3-9152-E52FFBB88992 Q35154170-569FE157-F131-41C0-8073-395DA31C029C Q35188192-DA4FF8DF-538C-415C-ABD9-B45A4BFAB7B0 Q36056627-8BF974E2-9243-4283-A712-3F30F26FBD79 Q36216363-664EEAEB-64AC-4D65-918B-DB9BDB3E78F9 Q36922260-12750A85-6D47-47E0-BF96-ED1AB5F3A9AF Q36950893-E0A9F168-3AED-4103-BB2A-4E40A5FD234D Q36989900-E2E530E1-4EB1-4B9D-816E-ED25C82F2086 Q37090829-977C9D75-AE01-4222-AA76-3C97DC4CA398 Q37243228-B2F3BB96-FE8D-4AFE-A465-9E44AA272AED Q37273461-7A55A375-D000-41EB-8167-3B89496F570E Q37323537-6738A385-8EBA-40E5-95F8-D66B7C2CC4C8 Q37403194-7ECD08DF-7C62-425C-BF5F-077EA4AE7B5B Q37573768-B5E0AF17-3426-437E-97C7-8CDDE6AF4B35 Q37672128-8AF6C5CF-F38A-4E8A-B192-AB800D161AD3 Q37893687-D86D9339-58E7-4808-808B-5D143BC60650 Q38028654-AF7CFF9E-25A6-4D57-9584-6DE89EC0A519 Q38115691-FCFC0078-9601-40EB-8BD1-82AE508AC709 Q38126913-46844453-8EE7-4149-90D8-2312C1F5B140 Q38131758-D1996D7C-DB98-4500-BD50-1F92CB6F7C48 Q38416739-6FA11E5C-AC27-48AF-A2E1-11CE0B6AD549 Q38752663-307FBA1A-A0B1-4F08-BF0E-4F2A139D418A Q39080325-B8442474-D3A0-426C-8CA5-876F1B2FFB47 Q39337108-9416C32D-6261-4049-AB8E-2439407D7546 Q39711072-0A950E65-3738-43B9-8B82-00BE8B404BD7 Q41762205-78F23C02-84BE-46A3-A829-E4F9CC1FDECA Q41825921-A5C190A2-A497-43A8-A9DA-CF0B7EEDA85F Q41909859-4365EE6A-9E73-4F19-8B13-4E86D4D49E5E Q43041424-1E07EB63-B3B4-4E83-8E6C-8600603FCAD1 Q46242617-470E2D72-7B3F-44A1-9BE9-C5A18650BF22

P2860

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

http://www.wikidata.org/entity/Q34574834

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@ast

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@en

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@nl

type

label

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@ast

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@en

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@nl

prefLabel

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@ast

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@en

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@nl

P1433

Q34574834-A4CEC565-679C-4D33-9F02-DF726163FAFA

P1476

Q34574834-A883E25B-442E-4F90-81CC-9EF9CB3967C7

P2093

Q34574834-C418F568-FCC7-45A7-A24D-F60CC37D0DD8

Q34574834-C934D3EA-322B-4C6D-A393-43457E38F169

Q34574834-CDA3CAAB-805F-4D7B-B41F-FBCA466B1D71

P2860

Q34574834-0223CCBF-7D9A-444C-9433-68E7294AA6D3

Q34574834-150646F3-B01F-4D8B-9C7A-966A900D1465

Q34574834-17F5FB5B-C55F-4348-9B31-B9E830AEC4C8

Q34574834-19225F32-AA4C-4161-B954-A6E1EF5DDF6E

Q34574834-1ED3973C-D310-44CE-92F8-736375DD17C6

Q34574834-20DF70E4-E756-4150-B0DE-C02215CB90E3

Q34574834-21A18ABC-7652-4431-890C-BB552FDC0523

Q34574834-232EA4E4-059E-4D36-A812-1074455544A5

Q34574834-2558AFAB-3A32-4E64-88D7-314FC310BF52

Q34574834-2CBF32BD-3884-4AE0-81B5-41E62C4DB751

P304

Q34574834-EEE19579-0C10-4B48-AA64-F021EB399297

P31

Q34574834-C9267869-9927-4991-8E94-9581CC1069AE

P356

Q34574834-7A0B66FC-E34D-4CED-9A4F-AA31C2E630FB

P407

Q34574834-EC2A80DA-36D9-4DDE-9F63-D470E252BEAE

P433

Q34574834-DD036B81-28FA-4F17-A6AC-3116981C6FFA

P478

Q34574834-C491EC75-3CBD-425F-95AC-5EDC4DC5FA70

P577

Q34574834-717B3F9B-40C4-4AAC-94BB-53A30DE52961

P5875

Q34574834-4B5174CA-E9F1-4A26-8A4D-833294BCD9CF

P698

Q34574834-A24A67DB-A76D-453B-A9F8-84CC631DC698

P921

Q34574834-9397C442-144F-4CE6-A770-6FF36BCBFCDB

P356

14712598.6.11.1161

P1433

Expert Opinion on Biological Therapy

P1476

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

@en

P2093

Kenya Shitara

http://www.w3.org/2001/XMLSchema#string

Mitsuo Satoh

http://www.w3.org/2001/XMLSchema#string

Shigeru Iida

http://www.w3.org/2001/XMLSchema#string

P2860

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Reshaping human antibodies for therapy

Replacing the complementarity-determining regions in a human antibody with those from a mouse

Molecular cloning of mouse alpha-1,6-fucosyltransferase and expression of its mRNA in the developing cerebrum

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Ancestral exonic organization of FUT8, the gene encoding the alpha6-fucosyltransferase, reveals successive peptide domains which suggest a particular three-dimensional core structure for the alpha6-fucosyltransferase family.

P304

1161-1173

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.6.11.1161

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6746745

http://www.w3.org/2001/XMLSchema#string

P698

17049014

http://www.w3.org/2001/XMLSchema#string

P921